September 10, 2025Consilium MedicumOpen Access

The effect of extended release metformin on MRI parameters of left ventricular remodeling in patients with prediabetes and heart failure with preserved ejection fraction

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Randomized trial shows metformin XR reduces left ventricular mass in prediabetes and HFpEF patients, suggesting cardiac benefits.

Patients using metformin XR showed a significant decrease in left ventricular mass after 12 months.
MRI assessments indicated a reduction in epicardial fat thickness by 16.7% in treated patients.
Metformin XR also contributed to weight loss and reduced glycated hemoglobin levels in patients.
No correlation was found between reductions in left ventricular mass and body mass index after treatment.

Цыганкова et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark